Search | Clinical Trials Finder

Conditions: Lupus Nephritis (LN)
Interventions: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Fulvestrant, Capivasertib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 818 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • Orange, California • San Francisco, California + 19 more

Conditions: Depression
Interventions: Risperidone and placebo comparator; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Menopause Related Conditions
Interventions: Salmon protein hydrolysate (SPH) powder formulated into a tablet format, Microcrystalline Cellulose; Dietary Supplement
Lead sponsor: Hofseth Biocare ASA; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Orthostatic Hypotension
Interventions: Midodrine HCl, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Boca Raton, Florida • New Port Richey, Florida • Lenexa, Kansas + 9 more

Conditions: Acute Leukaemia
Interventions: Daunorubicin, Cytarabine, Eltrombopag, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 14
States / cities: Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more

Conditions: Dedifferentiated Liposarcoma
Interventions: Selinexor, Placebo; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 12 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 26
States / cities: Los Angeles, California • Santa Monica, California • Stanford, California + 18 more

Conditions: Hepatitis C
Interventions: INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Anaheim, California • La Jolla, California • San Francisco, California + 3 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more

Conditions: Colitis Ulcerative
Interventions: SAR441566, SAR441566 matching Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 19
States / cities: Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more

Conditions: Opioid Use Disorder
Interventions: BI 1356225, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Alamitos, California • Los Angeles, California • Decatur, Georgia + 2 more

Conditions: Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
Interventions: Itacitinib, erlotinib, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Ogden, Utah

Conditions: Pre-hypertension, JNC 7 Stage I Hypertension
Interventions: Allopurinol, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Intraocular Pressure (IOP), Healthy Adult
Interventions: Eplerenone, Microcrystalline Cellulose NF (placebo); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: RSV Infection
Interventions: RSM01, Placebo; Drug · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years to 49 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Cocaine Dependence
Interventions: Propranolol, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Constipation
Interventions: linaclotide acetate, Matching placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 60
States / cities: Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 55 more

Conditions: Hot Flashes
Interventions: Fezolinetant, placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 65
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Cardiovascular Disease, Interventional Cardiology
Interventions: Aspirin, Placebo, ticagrelor; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Steatoblepharon
Interventions: XAF5 (concentration A: 0.1%), XAF5 (concentration B: 0.035%), Matching placebo; Drug
Lead sponsor: Topokine Therapeutics, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 6
States / cities: Newport Beach, California • Santa Ana, California • Danbury, Connecticut + 3 more

Conditions: Alzheimer Disease
Interventions: Simufilam 100 mg oral tablet, Placebo; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Gilbert, Arizona • Surprise, Arizona • Imperial, California + 12 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
Interventions: Cagrilintide, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 25
States / cities: Concord, California • Fresno, California • Palm Springs, California + 22 more

Conditions: Low Back Pain
Interventions: Hydrocodone ER, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 54 more

Conditions: Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions: Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more

Search by objective public record fields.

Dapagliflozin in Active Lupus Nephritis

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Risperidone and Suicidality in Major Depressive Disorder

ProGo Menopause Wellbeing Study

Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Selinexor in Advanced Liposarcoma

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Center of Research Translation (CORT) Project 2

Eplerenone and IOP in Healthy Adults

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

Effects of Propranolol on Responses to Drug-Related Imagery Scripts

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.